The recent upsurge of interest in microRNA (miRNA) is partly attributed to the discovery of the novel roles of miRNAs in many physiological and pathological processes, including tumor development. Research on breast cancer metastasis has also focused on the concept of miRNA, which can act either as promoters or as suppressors of metastases. This review will focus on a series of recent studies that demonstrate the involvement of miRNAs in breast cancer metastasis and will briefly describe various pathways of miRNA-regulated metastasis. Finally, future prospects will be discussed for the potential role of miRNAs as predictive markers and therapeutic agents for patients with breast cancer metastases.
Introduction
Most breast cancer deaths are due to the development of metastases, which is the culmination of neoplastic progression. The metastatic process involves multiple sequential steps: cells spread from the local mammary tumor to enter body cavities or, more commonly, the circulatory system (lymphatics or blood vasculature), evade the immune system, survive during transport until they arrest in a secondary organ (such as bone, brain and lung), undergo extravasation and initiate either intra-vascular or extra-vascular proliferation at ectopic sites (colonization) in response to local growth factors (Tavazoie et al., 2008; Hedley and Chambers, 2009 ). Each step in the development of metastases requires the coordinated spatio-temporal expression of proteins. Although the molecular mechanism underlying each step is still obscure, only a few cells in a primary tumor are believed to be able to complete all the steps and give rise to metastases (Fidler, 1975; Waghorne et al., 1988; Chiang and Massague, 2008; Wang et al., 2009) . Epithelial-mesenchymal transition (EMT) is thought to be necessary for the progression of benign tumor cells to invasive and metastatic cells or at least an alternative program (Thiery, 2002; Hanahan and Weinberg, 2011) . On the other hand, the cancer stem cell (CSC) hypothesis states that cancers (and metastases) develop from a subset of malignant cells that possess stem cell characteristics (Li et al., 2007) , which may render the invasive capability of carcinoma cells and may be helpful in metastatic progression, as shown in Figure 1 .
MicroRNAs (miRNAs) are small non-coding RNA molecules ranging in size from 19 to 24 nucleotides, which regulate gene expression in a sequence-specific fashion (Nicoloso et al., 2009) . Following incorporation into the ribonucleoprotein complex RNA-induced silencing complex, miRNAs bind to and interact with the 3 0 untranslated region (UTR) of target mRNAs through complementarity with the first 2 to 8 nucleotides at the 5 0 end of the miRNA. If the miRNA perfectly matches its target sequence, the mRNA is degraded by Ago2-RNA-induced silencing complex. However, if the miRNA contains mismatches to its target, it functions as an endogenous trigger of the RNA interference pathway, and thus translation of the target mRNA is blocked by Ago1-RNA-induced silencing complex (Fo¨rstemann et al., 2007) . The imperfect match opens up the possibility of multiple targets for one miRNA (Filipowicz et al., 2008) .
It has been demonstrated that miRNAs regulate the expression of a plethora of mRNAs and proteins that have important roles in tumor generation and development. Several studies have indicated that some miRNAs can act either as oncogenes or as tumor suppressors by silencing target protein-coding genes (Calin et al., 2004; Lu et al., 2005) . Recent reports imply multiple functions of miRNAs in breast cancer metastasis. A series of studies have demonstrated that some miRNAs are remarkably reduced or completely eliminated, whereas other miRNAs are aberrantly accumulated in metastatic breast cancer specimens relative to non-metastatic specimens (Table 1 ). The deregulation of miRNA abundance appears to be a general trait of metastatic cancers. These deregulated miRNAs, referred to as metastamir (Hurst et al., 2009b) , can be correlated with EMT/MET, stemness and multiple steps of the metastatic cascade.
miRNAs in EMT/MET and metastasis
EMT is an important pivotal cellular program that induces rapid changes in the shape and motility of epithelial cells (Polyak and Weinberg, 2009) . During this process, cells lose their cell-cell and cell-matrix contacts and epithelial polarity, gain the disseminated cell migration ability and become motile mesenchymal cells (Thiery, 2002) . Mesenchymal-epithelial transition (MET) is the inverse process of EMT. Increasing evidence indicates that the early stages of the metastatic process are similar to EMT, but at later stages following extravasation, metastasizing cells start to settle down in their target tissue and undergo a differentiation process MicroRNA-mediated breast cancer metastasis L Wang and J Wang similar to MET (Baum et al., 2008; Yang and Weinberg, 2008) . Therefore, the anomalous activation of either EMT or MET may increase the invasive and metastatic capabilities of tumor cells and may result in a poor clinical outcome. These processes are stimulated by extracellular cytokines, such as transforming growth factor-b (TGF-b), or intracellular cues, such as Ras and Twist (Polyak and Weinberg, 2009; Kang and Massague´, 2004) . Multiple miRNAs have been reported to act as crucial regulators of the EMT/MET processes and metastasis. The known regulatory mechanisms of these miRNAs involve proteins such as E-cadherins, ZEB1/2, TGF-b, Akt isoforms, Dicer and others ( Figure 2 ).
miRNAs regulate EMT/MET through E-cadherins, ZEBs and TGF-b E-cadherin, an important regulator of EMT/MET, can be effected by many miRNAs through different mechanisms. By targeting E-cadherin mRNA, miR-9 may initiate EMT and promote breast cancer metastasis. miR-9 levels were significantly elevated in primary breast tumors from patients with diagnosed metastases in comparison with those from metastasis-free patients (Ma et al., 2010b) . One possible explanation for this result is that miR-9 can promote cell motility and invasiveness and thus enable non-metastatic breast tumor cells to form micrometastases. Interestingly, miR-9-induced EMT in a cell-type-dependent and context-dependent manner, as miR-9-induced vimentin expression in cultured immortalized human mammary epithelial cells, but not in the breast cancer cell line SUM149 (Ma et al., 2010b) . Several EMT-inducing factors, such as ZEB1 (d-EF1), ZEB2 (SMAD-interacting protein 1 (SIP1)), Twist1, SNAIL (SNAI1), Slug (SNAI2), TGF-b and E47, are known to repress E-cadherin transcription and could participate in tumor invasion and metastasis by binding to the two bipartite E-box motifs within the E-cadherin promoter (Kang and Massague´, 2004; Korpal et al., 2008; Park et al., 2008; Pawelek and Chakraborty, 2008; Yang and Weinberg, 2008; Dykxhoorn et al., 2009) . The miR-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429 ) and miR-205, which were reported to be essential in regulating tumor metastasis, could directly target the mRNA of ZEB1 and ZEB2 (Christoffersen et al., 2007; Hurteau et al., 2007; Bracken et al., 2008; Burk et al., 2008; Park et al., 2008) . Thus, downregulation of these miRNAs in cells may lead to EMT initiation by repressing E-cadherin transcription and promoting vimentin transcription. In contrast, increasing the level of miR-200 could induce MET in MicroRNA-mediated breast cancer metastasis L Wang and J Wang both normal and cancer cell lines, reducing the motility and aggressiveness of the highly metastatic human breast cancer cell line MDA-MB-231 (Korpal et al., 2008; Park et al., 2008) . TGF-b is a crucial inducer of ZEB1/2 expression and EMT progression. Enforced expression of the miR-200 family alone was sufficient to prevent TGF-b-induced EMT . It has also been shown that all five members of the miR-200 family and miR-205 were markedly downregulated in cells that had undergone EMT in response to TGF-b.
Metastatic breast cancer cells need to acquire epithelial properties to complete their metastatic progress and form macroscopic metastases at distant organs. Data from miRNA microarrays and quantitative RT-PCR indicated that miR-200 family promoted reversion of the mesenchymal phenotype and facilitated the establishment of macroscopic metastases. In fact, the expression of miR-200 family is elevated in mouse breast cancer cells (4T1) that form macroscopic metastases, as compared with the isogenic mouse breast cancer cells (4TO7) that invade distant tissues but are unable to colonize. Overexpression of miR-200s in 4TO7 cells enabled the cells to metastasize to the lung and liver (Dykxhoorn et al., 2009) . As miR-200 family and ZEBs are linked in a double-negative feedback loop, the reversible system endows breast cancer cells with the capacity for EMT initiation to enhance their motility and invasive properties, while subsequently to still be able to undergo MET in order to form macroscopic metastases. Accordingly, the context-depending role of miR-200 family members in metastasis is an interesting example for the plasticity of miRNA function.
miRNAs regulate EMT/MET by targeting Dicer
Dicer, an RNase III endonuclease, was first recognized for its role in generating the small interfering RNAs that mediate RNA interference (Bernstein et al., 2001) and was later shown to cleave pre-miRNAs further to generate their mature forms in the cytoplasm (Grishok et al., 2001; Hutva´gner et al., 2001; Bartel, 2009) . Dicer was thought to be essential in stem cell maintenance including auto-renewal and proliferation (Jin and Xie, 2007) . Frequent deletion of Dicer1 was observed in the human cancer genome, and enforced Dicer1 deletion caused the inhibition of tumorigenesis . A low level of Dicer was also observed in breast cancer cell lines with a mesenchymal phenotype or with distinct metastatic bone derivatives (Grelier et al., 2009) . These observations indicate a dual role of Dicer in cancer: it is essential for proliferation and cell survival but is a barrier against metastatic spread to distinct organs. Recently, a report highlighted a new pathway by which Dicer inhibition drifts epithelial cancer toward a less-differentiated, mesenchymal fate to foster metastasis (Martello et al., 2010) . Dicer is the target of miR-103/ 107, whose expression is associated with metastasis and poor outcomes in breast cancer patients. Both the expression of Dicer and global mature miRNAs were downregulated in MDA-MB-231 cells expressing miR-103/107. These findings are consistent with clinical observations showing that patients with higher miR-103/107 level display a significantly higher probability of developing breast cancer metastases. At the cellular level, a key event fostered by miR-103/107 is induction of EMT, attained by decreasing miR-200 levels. Moreover, miR-107 controls the levels of ZEB1/ZEB2 in a miR-200-dependent manner. In conclusion, miR-103/ 107 may attenuate miRNA biosynthesis by regulating the expression of Dicer, thus enhancing the migratory capacity of the cells in vitro and the metastatic dissemination in vivo.
Interestingly, recent work found that TAp63, a p53 family member and suppressor of tumorigenesis and metastasis, could regulate Dicer by binding to and transactivating the Dicer promoter (Su et al., 2010) . Moreover, the modulation of Dicer1 expression in TAp63À/À mouse embryonic fibroblasts reduced and prevented the ability of these cells to invade while the knockdown of Dicer1 in wild-type mouse embryonic fibroblasts could increase invasiveness in vitro, suggesting that reduction of Dicer expression may increase cell invasion. The authors also found that TAp63 also transactivates miR-130b, a miRNA associated with metastasis and processed by Dicer. Upregulation of Dicer1 and miR-130b expression could markedly affect the metastatic potential of cells lacking TAp63. Through the coordinate transcriptional regulation of Dicer and miR-130b, TAp63 suppresses tumorigenesis and metastasis. These data provide a novel understanding of the pathway of Dicer and miRNAs in regulating tumor metastasis.
miR-29a regulates EMT/MET by targeting Tristetraprolin (TTP)
TTP is a protein involved in the degradation of mRNA with AU-rich 3 0 UTR sequence. In cooperation with oncogenic Ras signaling, the knockdown of TTP can lead to EMT and cancer metastasis (Gebeshuber et al., 2009) . miR-29a regulates the expression of TTP by binding to two regions in the 3 0 UTR. Thus, miR-29a may be involved in EMT and breast cancer metastasis through TTP. Previously, the expression of the miR-29 cluster (29a, 29b and 29c) has been shown to be downregulated in lung cancer, and these miRNAs were thought to be involved in epigenetic alteration of tumor metastasis (Fabbri et al., 2007) . Recent, evidence has indicated that miR-29a is a crucial modulator of EMT in breast cancer metastasis (Gebeshuber et al., 2009) . miR-29a was also shown to promote mesenchymal properties and metastasis of Ras-transformed mouse mammary epithelial cells by suppressing TTP expression. Greatly enhanced miR-29a and reduced TTP levels were observed in patients with invasive breast carcinomas.
miR-448 regulates EMT/MET through NF-kB NF-kB is a protein complex that controls the transcription of DNA. Aberrant activation of NF-kB was frequently observed in cancers and was reported to be involved in metastasis (Karin, 2006; Van Waes, 2007; Sethi et al., 2008) . It has been revealed that NF-kB can form a positive feedback loop with miR-448 through EMT to regulate metastasis in chemotherapy response (Li et al., 2011) . Adriamycin-activated NF-kB directly binds the promoter of miR-448 to suppress its transcription. Suppressed miR-448 induces EMT by directly targeting special AT-rich sequence-binding protein-1 mRNA, leading to elevated levels of amphiregulin, which increases epidermal growth factor receptormediated Twist1 expression and ultimately promotes metastasis. Interestingly, upregulated epidermal growth factor receptor can also activate NF-kB through the PI3K/AKT pathway, suggesting that there is a positive feedback loop between NF-kB and miR-448.
Stemness and miRNA-regulated metastasis
It has been a decade as Irving Weissman and his coworkers first suggested the role of CSCs in metastasis (Reya et al., 2001) . This theory derives from the CSC hypothesis, which states that cancers develop from a subset of malignant cells that possess the characteristics of both cancer cells and stem cells. Stem cells have an active DNA repair capacity and exhibit resistance to apoptosis. Additionally, their population expands rapidly. Moreover, they express several transporters (efflux pumps for drugs and toxins) that are the major multidrug-resistance genes in cancers (Hirschmann-Jax et al., 2004) . All of those factors could contribute to the survival of CSCs and repopulate a metastasis after cytotoxic drug treatment or radiation (Dean et al., 2005) . It has also been proposed that CSCs possess invasive and migratory characteristics (Brabletz et al., 2005) . Thus, CSCs may have all of the necessary attributes to result in a metastasis (Karnoub et al., 2007; Li et al., 2007) .
Recent reports have linked an important miRNA, let-7, to stem cell maintenance and have indicated a new connection between metastasis and stem cell formation. let-7 was suggested to inhibit stem cell self-renewal and undifferentiated status in both normal mammary tissue and breast cancer cells. Breast cancer initiating cells isolated from patients after receiving chemotherapy were found to be devoid of let-7 expression (Yu et al., 2007) . When plated under conditions favoring differentiation, let-7 was strongly upregulated over a course of 5 days. It is hypothesized that stem-like cancer cells lack let-7 expression. The overexpression of let-7 inhibits the proliferation of the undifferentiated cell proportion in vitro and metastasis in vivo whereas the inhibition of let-7 activity by antisense oligonucleotides promotes the self-renewal potential of human breast cancer cell line (SKBR3) (Esquela-Kerscher and Slack, 2006) . Moreover, reducing let-7 levels in breast CSCs transplanted in mice could increase tumorigenic and metastatic capability (Yu et al., 2007) EMT is aberrantly activated in cancer stem cells, and the active transition could promote malignant characteristics (Polyak and Weinberg, 2009) . By virtue of EMT properties, stem cells are better equipped to complete the execution of the metastatic program and give rise to macroscopic metastasis. As miR-200 family members are crucial regulators of EMT, they bridge metastasis and stemness, with ZEBs (targets of the miR-200 family) mediating the connection. The ZEB/miR-200 feedback loop acts as a molecular motor of cellular plasticity in breast cancer. Recently, ZEB/miR-200 has been proposed to be a driving force for cancer progression toward metastasis by controlling the phenotype of cancer stem cells (Brabletz and Brabletz, 2010) . In pancreatic cancer cells, ZEB1 increases stem-cell properties and the tumorigenic capacity (Wellner et al., 2009) MicroRNA-mediated breast cancer metastasis L Wang and J Wang Conversely, ZEB1 could inhibit the expression of miR-183, miR-203 and miR-200 (Wellner et al., 2009) . These miRNAs together target stemness-associated factors, such as BMI1, SOX2 and KLF4. As an EMT activator and miR-10b regulator, Twist can induce stem-cell properties in mammary epithelial cells (Mani et al., 2008) ; therefore it may be another intermediary between stemness and breast cancer metastasis. The above data indicate that the miRNA-dependent regulation of EMT, stemness and metastasis could all be linked (Figure 3) . miRNA involvement in sequential metastatic steps miRNAs lead to extracellular matrix (ECM) modification The implementation of cancer metastasis requires the migration of cancer cells and the degradation of the ECM proteins. Ample studies suggest that miRNAs have a critical role in the modification of the ECM (Figure 4 ). These miRNAs are highly expressed in the microenvironment of most solid tumors and participate in multiple steps of malignant transformation, including metastasis. According to an elegant study of miRNA array profiling, miR-335 regulates several genes whose collective expression is associated with ECM interactions and risk of distant metastasis in MDA-MB231cells and their derivative cells specific for lung and for bone metastases (Tavazoie et al., 2008) . The targets for miR-335 are identified to be the transcription factor SOX4, ECM component tenascin C, receptor type tyrosine protein phosphatase (PTPRN2) and c-Mer tyrosine kinase (MERTK). SOX4 transcription factors are known to regulate progenitor cell development and migration (Hoser et al., 2007) while miR-335 targets SOX4 by its SRY-box. Thus, miR-335 is believed to be a suppressor of metastasis in human breast cancer.
miR-373 and miR-520c, two members of the same miRNA family sharing similar seed sequences (Bernstein et al., 2001) , were identified as functional metastasispromoting miRNAs in breast cancer . Clinically, miR-373 was upregulated in lymphnode metastases compared with the primary tumors from 11 pairs of matched samples. miR-520c was also overexpressed in breast cancer metastases compared with primary tumors. The expression of both miRNAs inversely correlated with the expression of CD44. This result can be explained by their binding to the 3 0 UTR of CD44 mRNA to suppress CD44 . Moreover, upregulation of miR-373 or knockdown of CD44 can specifically increase tumor invasion and migratory potential. CD44, encoding a cell surface receptor for hyaluronan, is lost in breast cancers with high metastatic potential and acts as a suppressor of metastasis in cancer. Thus, miR-373 and miR-520 induced the loosening of ECM connections through suppression of CD44 and thus promote migration and subsequently increase metastasis in vivo. Additionally, E-cadherin promoter is another target of miR-373 (Place et al., 2008) , and miR-373 may promote migration and metastasis in part by targeting E-cadherin. Taken together, the same miRNA may have different targets in breast cancer cells and may interact with the microenvironment to select which target to regulate in a specific situation. miRNAs regulate cell migration and invasion Cellular migration and invasion are fundamental processes required for a primary cancer to spread and form metastases, and miRNAs could regulate these processes ( Figure 5 ). miR-10b is the first-found miRNA relevant to breast cancer metastasis (Ma et al., 2007) . miR-10b silencing reduced the invasive properties of MDA-MB-231 cells.Ectopic expression of miR-10b dramatically increased the invasive potential of the nonmetastatic breast cancer cell line SUM149 in vivo but had no effect on growth rate of the tumor. Furthermore, induction of miR-10b expression initiated the formation of lung and peritoneal metastases. These results were confirmed by using a class of chemically modified Figure 4 miRNAs regulate breast cancer metastasis through ECM modification. miR-373 and miR-520 promote the loosening of ECM connections through suppression of CD44 whereas miR-335 is involved in ECM modification through suppression of TNC (tenascin C) and SOX4 expression. miR-21 represses the expression of various tumor suppressors such as NFIB, PDCD4, TIMP1, marcks, Spry2, maspin, Timp3, PECK, BMD6, RACK and PTEN. Some of them could modulate ECM interactions in breast cancer and be involved in the regulation of metastasis.
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anti-miRNA oligonucleotide (antagomirs), which demonstrated that systemic treatment of tumor-bearing mice with miR-10b antagomirs could significantly suppresses breast cancer metastasis without reducing primary mammary tumor growth (Ma et al., 2010a) . Detailed molecular analysis identified a pathway in which the pro-metastatic gene Twist1 transactivates miR-10b by binding directly to its putative promoter. The transcription factor Twist, upregulated by the LMP1 protein (Horikawa et al., 2007) , is responsible for many steps in metastasis (Yang et al., 2004) . Similarly to Twist1, miR10b overexpression is not an early event during tumor progression, and its expression at early breast cancer stages does not correlate with distant recurrence free survival (Gee et al., 2008) . However, miR-10b can inhibit the translation of the mRNA encoding homeobox D10 (HOXD10), a transcription factor known for its roles in cell motility. Restrained by HOXD10, the pro-metastatic gene RhoC was found to be responsible for the miR-10b-induced migratory and invasive phenotype. In addition to HOXD10, miR-10b may target additional genes that affect the metastasis of breast carcinoma (Moriarty et al., 2010) . Tiam1 (T lymphoma invasion and metastasis 1), a guanidine exchange factor for Rac, is also a potential target. miR-10b repressed Tiam1 expression in breast carcinoma cells by interacting with the 3 0 UTR of Tiam1. In addition, miR-10b inhibits Tiam1-mediated Rac activation, and influences migration and invasion of breast carcinoma cells.
Concomitantly, miR-21 can post-transcriptionally downregulate several tumor suppressor genes such as tumor suppressor programmed cell death 4 (PDCD4), maspin, tissue inhibitor of metalloproteinase 3 (TIMP3) and tropomyosin 1 (TPM1), thus stimulating invasion and metastasis (Zhu et al., , 2008 Frankel et al., 2008; Huang et al., 2009; Selaru et al., 2009) . Moreover, miR-21 was shown to be regulated by several tumor metastasis associated genes, such as TGF-b, EGF and BMPs (Davis et al., 2008; Gabriely et al., 2008; Du et al., 2009) . It has been demonstrated that BMP6, an important factor in bone metastasis, inhibited miR-21 expression in breast cancer by repressing ZEB1 and AP-1 (Du et al., 2009) . Furthermore, miR-21 is involved in HER2/neu-induced cell invasion, mediated via the MAP kinase pathway upon the stimulation of HER2/ neu signaling in breast cancer cells (Huang et al., 2009) . Thus, it can be concluded that miR-21 can increase invasion and migration as well as decrease apoptosis in breast cancer.
miR-146a/b inhibit invasion and migration of breast cancer cells by targeting IRAK1 and TRAF6 and by downregulating NF-kB (Bhaumik et al., 2008) . Similar studies extended in vivo showed miR-146a/b could suppress prostate cancer metastasis by targeting metastatic promoter EGF receptor (Hurst et al., 2009a) and ROCK1 (Lin et al., 2008) . It has been verified that breast cancer metastasis suppressor 1 (BRMS1) decreases metastasis-promoting miRNAs (miR-10b, -373 and -520c) and increases expression of metastasissuppressing miRNAs (miR-146a, -146b, miR-21 and -335) (Edmonds et al., 2009) . Correspondingly, BRMS1 can inhibit breast cancer metastasis in xenograft and syngeneic models without blocking tumorigenesis and orthotopic tumor growth Phadke et al., 2008) . Previous studies have shown that BRMS1 forms complexes with SIN3, histone deacetylases and selected transcription factors that modify metastasisassociated gene expression, such as epidermal growth factor receptor , uPA (Cicek et al., 2005) and osteopontin . Moreover, BRMS1 regulates metastasis associated miRNAs partly through altering the expression of metastasis-associated genes (Edmonds et al., 2009) . Indeed, BRMS1 can decrease the expression of Twist and RhoC, which are upstream and downstream of miR-10b, respectively (Ma et al., 2007) . miRNAs regulate cell senescence and apoptosis Cellular senescence and apoptosis act as barriers to cancer progression. It has been reported that miR-22 induced cellular senescence by directly targeting CDK6, SIRT1, and Sp1 . Thus, miR-22 could decrease tumor cell motility and inhibit tumor cell invasion in vitro, and synthetic miR-22 delivery suppressed breast carcinoma growth and metastasis in a mouse model by inducing cellular senescence. In a previous study, miR-22 was reported to be a tumor suppressor with an inhibitory impact on the Estrogen Receptor alpha-dependent proliferation of breast cancer cells (Pandey and Picard, 2009) . Recently, it has been demonstrated that the expression of miR-22 was consistently downregulated in metastatic breast cancer cells (Patel et al., 2011) . Moreover, there is evidence that Figure 5 miRNAs regulate breast cancer metastasis by interfering with invasion and migration. As a downstream target gene of Twist and breast cancer metastasis-suppressor 1 (BRMS1), miR-10b increases the invasiveness and metastatic potential of breast cancer cells mainly in two ways. It activates Rho GTPase C (RhoC) by inhibiting homeobox D10 (HOXD10), or inhibits Rac gene by suppressing T lymphoma invasion and metastasis 1 (Tiam1). Both RhoC and Rac are involved in metastasis. Transcriptionally activated by HOXD10, miR-7 inhibits the metastasis-associated gene Pak1. Upregulated by BRMS1, miR-146 directly downregulates transcription of EGFR (epidermal growth factor receptor), CXCR4 and ROCK1, which are all relevant to cell mobility.
MicroRNA-mediated breast cancer metastasis L Wang and J Wang oncogenes ERBB3, CDC25C and EVI-1 are also miR-22 targets, which are over-expressed in metastatic cells . Knockdown of miR-21 in breast cancer MCF7 cells increased cellular apoptosis and decreased cell proliferation possibly through downregulation of Bcl-2 protein expression . Other studies have shown that miR-206 activates apoptosis by targeting NOTCH3 (Song et al., 2009) , while miR-200c sensitizes cells to apoptosis by targeting FAP-1 and regulating CD95 (Schickel et al., 2010) . Apoptosis of breast tumor-initiating cells could be inhibited by miR-30 reduction (Yu et al., 2010a) . miRNAs regulate angiogenesis Angiogenesis is essential for the growth of micrometastases. Upregulated in breast tumors, miR-9 performs double effects in metastasis, not only priming the cancer cells for EMT, but also stimulating angiogenesis (Ma et al., 2010b) . miR-9-mediated E-cadherin downregulation results in the activation of b-catenin signaling, which then contributes to upregulated expression of vascular endothelial growth factor and leads to increased tumor angiogenesis.
Recent findings revealed that miR-126 regulated angiogenic signaling and vascular integrity, and thus suppressed the growth of metastatic cells to form secondary tumors in the new organ environment (Fish et al., 2008; Harris et al., 2008) . miR-126 is lost in the majority of primary breast tumors from patients who relapse, and the loss of its expression associated inversely with distal metastasis-free survival (Tavazoie et al., 2008) . The restoration of miR-126 was known to reduce the overall tumor growth. miR-205 may bind to the 3 0 UTR of vascular endothelial growth factor-A and inhibit the suppression of vascular endothelial growth factor-A expression, which could stimulate tumor angiogenesis (Wu et al., 2009b) . miRNAs in the microenvironment participate in cancer metastasis According to the seed and soil hypothesis, different organs can support or limit the survival and growth of the micrometastasis (Talmadge and Fidler, 2010) . miRNAs may be involved in the interaction of breast cancer cells and the microenvironment, and miR-127, miR-197, miR-222 and miR-223 are representative miRNAs in this interaction (Lim et al., 2011) . They can all be transported from bone marrow stroma to breast cancer cells via gap junctions. After transport, these miRNAs directly target CXCL12 and reduce its levels, leading to a decrease in cell proliferation. Stromaderived exosomes containing miRNAs also contributed to breast cancer cell quiescence, although to a lesser degree than miRNAs transmitted via gap junctions. Thus, MDA-MB-231 and T47D breast cancer cells were observed arresting in the G(0) phase of the cell cycle when cocultured with bone marrow stroma. Thus, it was proposed that the transfer of miRNAs from bone marrow stroma to breast cancer cells might have a role in the dormancy of bone marrow metastases.
Conclusions and Future Perspectives
Although metastasis-related miRNAs have been recognized for less than 3 years, the explosive rate of discovery of these molecules is impressive. Novel miRNA genes have been discovered by bioinformatics approaches searching for evolutionary conserved stemloop structures in the genome, or identified by cloning all small RNAs from a certain tissue type or developmental stage and subsequently sequencing the subgroups, which fulfill the criteria for miRNAs (Berezikov et al., 2006) .
Obviously, miRNAs have opened up a new field of metastasis research, and new targets have been found every year ( Table 2 ). As we gain insight into the miRNAs signaling and orchestrating all the metastatic steps, it is becoming clearer that some pathways may provide potential therapeutic targets. What's more, these molecules may be used as prognostic markers for metastatic breast cancer. Strategies that manipulate miRNA expression levels in vivo provide novel treatments for this intractable disease. Anti-metastasis miRNAs are common, and novel drugs can act to restore their expression level. Conversely, some prometastasis miRNAs can be silenced or depressed, which may be useful to prevent metastases in patients. Methods of manipulating miRNA expression via antagomirs, miRNA sponges or viral/non-viral vectors may be useful for cancer treatment. Some miRNAs can be selectively packaged into microvesicles, actively secreted to the plasma, and delivered into recipient cells where the exogenous miRNAs can regulate target gene expression and recipient cell function . On the basis of this theory, miRNAs in the plasma of patients may be not only important biomarkers for cancer metastasis but also potential targets for drugs.
However, the challenge for developing miRNA-based therapeutics is yet to be overcome, because miRNAs and their targets form a complex network. It is often difficult to determine whether the biological effects are due to a single miRNA or whether they are due to the collective effects of multiple miRNAs, as many miRNAs are encoded as genetically linked clusters. Each miRNA has the potential to target a large number of genes (on average about 500 for each miRNA family) (Garzon et al., 2010) . Moreover, miRNAs not only regulate gene through 3 0 UTR interactions, but also could bind to the open reading frame or to the 5 0 UTR of their target genes, or even activate, instead of inhibition, gene expression in some cases (Stark et al., 2007; Ørom et al., 2008) . In addition, miRNAs can bind directly to DNA and thus regulate gene expression at the transcriptional level (Kim et al., 2008; Khraiwesh et al., 2010) . In addition to the complex and universal regulation of gene expression by miRNAs, the delivery, potential off-target effects, bioavailability and safety in humans should also be considerate when developing miRNAbased therapies. Overall, there is still a long way to go before miRNA-targeted therapies as effective approaches for the sequence-specific inhibition of miRNAs in breast and other tumors become a reality, and using miRNAs as diagnostic and prognostic markers remains a scientific and clinical challenge.
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